The Ledger

ZBH

Zimmer Biomet Holdings IncHealth Careinsider_universe

Last close $92.31Jun 28, 2026

Day −0.85%

Currently held

Agent 6 — Options Momentumlong
1 contracts · CALL $93 exp Jul 30, 2026 · entry $3.03
-$23.85 unrealized

Everything we've seen

·Jun 29, 12:16 PMstreamnews
Pixee Medical Names Kristoff Goson CEO, Signaling Major Push for U.S. Market Growth
CAMBRIDGE, Mass., June 29, 2026--Today, Pixee Medical announced the appointment of American healthcare executive Kristoff Goson as new Chief Executive Officer. A former senior executive at Zimmer Biomet, Goson will lead the company’s U.S. commercial expansion and global growth strategy as demand increases for more accessible and simplified surgical guidance technologies.
❖Jun 29, 11:00 AMnewsvia finnhub
Pixee Medical Names Kristoff Goson CEO, Signaling Major Push for U.S. Market Growth
CAMBRIDGE, Mass., June 29, 2026--Today, Pixee Medical announced the appointment of American healthcare executive Kristoff Goson as new Chief Executive Officer. A former senior executive at Zimmer Biomet, Goson will lead the company’s U.S. commercial expansion and global growth strategy as demand increases for more accessible and simplified surgical guidance technologies.
?Jun 26, 3:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ZBH is up ~2% intraday with no news catalyst identified. With only 15 minutes remaining until the forced close, there is minimal time for the move to extend further toward the +3% profit target. The macro context (T10YIE at 1.9σ below trend) is modestly supportive of long-duration sensitive sectors, but ZBH as a medical devices company is not a primary beneficiary of falling inflation expectations. The critical constraint here is time: 15 minutes is insufficient runway to expect meaningful additional upside. Late-session moves in the absence of a catalyst often see light-volume drift or mild mean reversion as participants flatten positions into the close. The setup does not meet the threshold for a continuation trade given the time limitation.
!Jun 26, 3:30 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
ZBH is up ~2% intraday with no news catalyst identified. With only 15 minutes remaining until the forced close, there is minimal time for the move to extend further toward the +3% profit target. The macro context (T10YIE at 1.9σ below trend) is modestly supportive of long-duration sensitive sectors, but ZBH as a medical devices company is not a primary beneficiary of falling inflation expectations. The critical constraint here is time: 15 minutes is insufficient runway to expect meaningful additional upside. Late-session moves in the absence of a catalyst often see light-volume drift or mild mean reversion as participants flatten positions into the close. The setup does not meet the threshold for a continuation trade given the time limitation.
✓Jun 26, 10:21 AMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on ZBH — 5-day return 5.94% with close above 20-day MA ($87.54). IV 23.7%. Sized 1 contract(s) at $3.03 premium.
❖Jun 24, 11:24 AMnewsvia finnhub
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
ISRG stands out over ZBH as stronger revenue growth, rising procedure demand, and expanding AI-driven innovation support better upside in 2026.
?Jun 24, 10:41 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ZBH is up 2.22% intraday with no attributable headline, suggesting this is flow-driven rather than news-driven. The move is meaningful but not extreme. Macro context shows 10Y inflation expectations (T10YIE) running 2.0σ below trend at 2.21, which is modestly supportive for rate-sensitive healthcare/med-device names like ZBH as lower real rate expectations can support longer-duration equity valuations. However, ZBH is not a pure long-duration play and the macro tailwind is modest. With 305 minutes remaining there is ample time for continuation, but also ample time for mean reversion. No catalysts to sustain buying pressure and no volume data to confirm conviction. Default lean is slight continuation given the magnitude of the move already printed and time remaining, but confidence is low — assigning modest above-50 probability.
!Jun 24, 10:41 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
ZBH is up 2.22% intraday with no attributable headline, suggesting this is flow-driven rather than news-driven. The move is meaningful but not extreme. Macro context shows 10Y inflation expectations (T10YIE) running 2.0σ below trend at 2.21, which is modestly supportive for rate-sensitive healthcare/med-device names like ZBH as lower real rate expectations can support longer-duration equity valuations. However, ZBH is not a pure long-duration play and the macro tailwind is modest. With 305 minutes remaining there is ample time for continuation, but also ample time for mean reversion. No catalysts to sustain buying pressure and no volume data to confirm conviction. Default lean is slight continuation given the magnitude of the move already printed and time remaining, but confidence is low — assigning modest above-50 probability.
❖Jun 10, 8:19 PMnewsvia finnhub
Why The Narrative Around Zimmer Biomet (ZBH) Is Shifting Without New Analyst Updates
Zimmer Biomet Holdings currently sits with no changes to its published price targets, so you are working with the same reference points that were already in place. With no fresh analyst commentary on record, recent market moves are not being framed by new Wall Street narratives. Read on to see how you can track future revisions and keep up with how the story around this stock evolves over time. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to...
▣Jun 10, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 100 @ $3.14 (+$7.16)
Stop: premium $3.14 ≤ trailing floor $3.35 (peak $4.47 × 0.75)
❖Jun 9, 10:30 AMnewsvia finnhub
Is Zimmer Biomet Holdings, Inc. (ZBH) A Good Stock To Buy Now?
Is ZBH a good stock to buy? We came across a bullish thesis on Zimmer Biomet Holdings, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ZBH. Zimmer Biomet Holdings, Inc.’s share was trading at $87.27 as of June 8th. ZBH’s trailing and forward P/E were 22.62 and 10.46 respectively according […]
?Jun 9, 10:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ZBH is up 1.76% today, a moderate but meaningful intraday move suggesting real buying interest. There are no news headlines to explain or amplify the move, which is common — institutional flow can drive price without a catalyst. The macro context shows T10Y2Y at 0.41, notably below trend, which is a mild headwind for cyclicals/medical devices (ZBH is an orthopedic device maker), but not a direct enough signal to fade this specific move. With 330 minutes remaining (essentially a full trading session still ahead), there is ample time for momentum to extend toward the +3% target. The move is below the 2-5% 'high conviction' threshold, so I treat this as ordinary momentum with no strong reason to expect a reversal. No reversal pattern is evident, and the setup meets the baseline continuation criteria. Probability is modestly above the 0.5 threshold — lean long but without strong conviction.
!Jun 9, 10:16 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
ZBH is up 1.76% today, a moderate but meaningful intraday move suggesting real buying interest. There are no news headlines to explain or amplify the move, which is common — institutional flow can drive price without a catalyst. The macro context shows T10Y2Y at 0.41, notably below trend, which is a mild headwind for cyclicals/medical devices (ZBH is an orthopedic device maker), but not a direct enough signal to fade this specific move. With 330 minutes remaining (essentially a full trading session still ahead), there is ample time for momentum to extend toward the +3% target. The move is below the 2-5% 'high conviction' threshold, so I treat this as ordinary momentum with no strong reason to expect a reversal. No reversal pattern is evident, and the setup meets the baseline continuation criteria. Probability is modestly above the 0.5 threshold — lean long but without strong conviction.
❖Jun 9, 10:07 AMnewsvia finnhub
Will ISRG's Cost Leverage Aid Margins Amid Tariff & Input Inflation?
ISRG lifts margins despite tariffs, using scale, cost cuts and da Vinci 5 adoption to offset inflation as 2026 cost pressures build.
❖Jun 9, 10:01 AMnewsvia finnhub
Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
Globus Medical is riding on musculoskeletal market growth with strong Q1 sales gains, double-digit spine growth, and rising trauma demand across key product lines.
✓Jun 8, 6:04 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on ZBH — 5-day return 5.26% with close above 20-day MA ($84.23). IV 26.7%. Sized 1 contract(s) at $3.07 premium.
❖Jun 8, 1:08 PMnewsvia finnhub
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Zimmer Biomet Holdings, Inc. (ZBH) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 10:40 AM EDTCompany ParticipantsIvan Tornos -...
✓Jun 8, 7:01 AMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on ZBH — 5-day return 6.07% with close above 20-day MA ($83.98). IV 27.2%. Sized 1 contract(s) at $3.14 premium.
▢Jun 7, 8:00 PMjournal
Agent 6 — Options Momentum opened long 100 @ $3.07
?Jun 4, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
!Jun 4, 7:02 AMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
?Jun 4, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.80 cash available; close=$84.98.
!Jun 4, 7:02 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $3.84 cash available; close=$85.00.
?Jun 3, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
!Jun 3, 6:06 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
?Jun 3, 6:05 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.84 cash available; close=$85.00.
!Jun 3, 6:05 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $2.42 cash available; close=$83.75.
?Jun 3, 3:41 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 5 minutes remaining until the forced close, there is essentially no time for meaningful continuation. The 1.74% move is modest but real, suggesting genuine buying interest. However, the macro context (T10Y2Y at 2.1σ below trend, bear-flattening pressure on defensives) is mildly unfavorable for ZBH, a medtech/defensive-adjacent name. More critically, at 5 minutes to cutoff, even a strong setup cannot realistically reach the +3% profit target from current levels (+1.26% still needed) before the 3:45 PM ET flatten. The time constraint alone is the dominant factor here, reducing continuation probability below the 0.5 threshold regardless of the underlying momentum signal.
!Jun 3, 3:41 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
With only 5 minutes remaining until the forced close, there is essentially no time for meaningful continuation. The 1.74% move is modest but real, suggesting genuine buying interest. However, the macro context (T10Y2Y at 2.1σ below trend, bear-flattening pressure on defensives) is mildly unfavorable for ZBH, a medtech/defensive-adjacent name. More critically, at 5 minutes to cutoff, even a strong setup cannot realistically reach the +3% profit target from current levels (+1.26% still needed) before the 3:45 PM ET flatten. The time constraint alone is the dominant factor here, reducing continuation probability below the 0.5 threshold regardless of the underlying momentum signal.
?Jun 3, 10:36 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
?Jun 3, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.42 cash available; close=$83.75.
!Jun 3, 7:02 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $8.58 cash available; close=$83.74.
?Jun 3, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
!Jun 3, 7:02 AMsignalseverity 0.13
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
?Jun 2, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
?Jun 2, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $8.58 cash available; close=$83.74.
!Jun 2, 6:04 PMsignalseverity 0.13
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
!Jun 2, 6:04 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $1.04 cash available; close=$82.94.
?Jun 2, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.04 cash available; close=$82.94.
!Jun 2, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $2.27 cash available; close=$82.93.
?Jun 2, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
!Jun 2, 7:01 AMsignalseverity 0.14
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
?Jun 1, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
!Jun 1, 6:04 PMsignalseverity 0.14
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
?Jun 1, 6:03 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
!Jun 1, 6:03 PMsignalseverity 0.14
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
?Jun 1, 6:03 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.27 cash available; close=$82.93.
!Jun 1, 6:03 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $29.62 cash available; close=$82.33.
?Jun 1, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $29.62 cash available; close=$82.33.
!Jun 1, 7:03 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +1. No hard veto conditions fired — no imminent earnings, no fundamental deterioration visible in filings (8-K metrics are empty, 10-Q filed normally), no going-concern language, and the sector is not in freefall (XLV ranks 3 of 11 by 30d relative strength, though it is underperforming SPY by ~5.86pts over 30 days, which partially qualifies the sector-wide dip signal at +1). The drop of 14.7% is just below the 15% threshold for the mean-reversion signal, so that does not score. No earnings within 30 days adds +1; macro is broadly neutral with VIX at only the 19th percentile (no elevated-VIX penalty) and the 10Y at 4.45% is just below the 4.5% headwind threshold (neutral for a defensive medtech name like ZBH). The absence of insider buying, unusual options flow, or any confirming signals keeps the score modest. Starting from the ~57% base rate for a fundamentally unimpaired large-cap dip, the +1 net score supports a marginally above-base probability.
?Jun 1, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
!Jun 1, 7:02 AMsignalseverity 0.15
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ZBH (Zimmer Biomet) is a large-cap medical device company with generally stable fundamentals, and the 14.7% drop from its 30-day high appears to be more macro/sector-driven than company-specific, given the absence of any negative news headlines or deteriorating filing metrics. Health Care (XLV) has underperformed SPY by -5.86pts over 30 days and today's sector flow proxy is deeply negative (-18.6M), suggesting this is largely a sector-wide headwind rather than idiosyncratic ZBH deterioration. However, evidence is sparse: no insider cluster buys, no unusual options call flow, no analyst upgrades, and SEC filings contain no visible metrics to anchor a valuation view. The macro environment is relatively benign (VIX at 19th percentile, yield curve positively sloped), which provides a mild tailwind but not enough to overcome the lack of confirming signals.
✓May 29, 6:03 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
Wanted to buy but only $9.19 cash available; close=$82.82.
?May 29, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.04 cash available; close=$82.82.
!May 29, 7:02 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $12.25 cash available; close=$84.41.
?May 29, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $9.19 cash available; close=$82.82.
!May 29, 7:01 AMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $6.30 cash available; close=$84.41.
?May 28, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $12.25 cash available; close=$84.41.
!May 28, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $1.29 cash available; close=$84.41.
?May 28, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
!May 28, 6:01 PMsignalseverity 0.14
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
?May 28, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $6.30 cash available; close=$84.41.
!May 28, 6:01 PMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $8.03 cash available; close=$84.41.
?May 28, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.29 cash available; close=$84.41.
!May 28, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$84.41.
?May 28, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $8.03 cash available; close=$84.41.
!May 28, 7:01 AMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $9.46 cash available; close=$84.41.
?May 27, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$84.41.
?May 27, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
!May 27, 6:01 PMsignalseverity 0.14
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
!May 27, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$84.41.
?May 27, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $9.46 cash available; close=$84.41.
!May 27, 6:01 PMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $21.36 cash available; close=$84.41.
❖May 27, 12:00 PMnewsvia finnhub
THINK Surgical Announces the TMINI® Miniature Robotic System 5,000th Procedure Milestone
THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announces that its TMINI® Miniature Robotic System has been used in its 5,000th total knee (TKA) procedure. The 5,000th case was recently completed by Dr. John Tiberi of Cedars-Sinai Orthopedics in Los Angeles, CA.
❖May 27, 11:53 AMnewsvia finnhub
3 Reasons to Sell ZBH and 1 Stock to Buy Instead
Over the past six months, Zimmer Biomet’s shares (currently trading at $85.45) have posted a disappointing 12.4% loss, well below the S&P 500’s 9.1% gain. This might have investors contemplating their next move.
?May 27, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$84.41.
!May 27, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $22.31 cash available; close=$85.50.
?May 27, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $21.36 cash available; close=$84.41.
▣May 26, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 100 @ $4.11 (-$120.13)
Stop: premium $4.11 ≤ trailing floor $4.31 (peak $5.75 × 0.75)
?May 26, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
?May 26, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $22.31 cash available; close=$85.50.
?May 26, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $2.08 cash available; close=$85.50.
❖May 26, 8:09 AMnewsvia finnhub
Is Zimmer Biomet Holdings (ZBH) One of the Best Robotic Surgery Stocks to Buy?
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the best robotic surgery stocks to buy. Canaccord cut the price target on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to $83 from $93 on April 29, and maintained a Buy rating on the shares. The firm stated that the company delivered a solid fiscal Q1 to start the year, […]
?May 26, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$85.50.
?May 26, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$85.50.
?May 22, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ZBH (Zimmer Biomet) is a large-cap medical devices company with no evidence of fundamental deterioration — no recent 10-Q/8-K filings flagging guidance cuts or going concerns, and no imminent earnings catalyst. The 12.8% drop from the 30-day high appears sector-driven rather than idiosyncratic: Health Care (XLV) ranks 10th of 11 sectors by 30-day relative strength and is down ~12.5pts vs. SPY over 30 days, suggesting broad sector pressure accounts for much of the decline. The base rate for a fundamentally sound stock recovering a 10%+ dip within 90 days is ~55-60%, but meaningful headwinds temper conviction.
?May 22, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
?May 22, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ZBH (Zimmer Biomet) is down 14.4% from its 30-day high with no visible fundamental catalyst in the evidence set — no earnings surprise, no SEC filings, no insider selling. However, the Health Care sector is deeply underperforming (rank 10/11, -13.87pts vs SPY over 30 days) with sharply negative sector flow (-$13.8M), suggesting this drop is largely sector-driven rather than idiosyncratic. The broad market is also under pressure today (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE 2.7, 2.5σ above trend) create a headwind for rate-sensitive healthcare names. With no confirmation signals — no insider buys, no unusual call flow, no analyst upgrades — the case for a rebound rests entirely on mean reversion in the sector, which is currently in a downtrend.
❖May 22, 4:30 PMnewsvia finnhub
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026. The cash dividend of $0.24 per share is payable on or about July 31, 2026 to stockholders of record as of the close of business on June 25, 2026.
?May 22, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ZBH (Zimmer Biomet) is a large-cap medical devices company with no evidence of fundamental deterioration — no recent 10-Q/8-K filings flagging guidance cuts or going concerns, and no imminent earnings catalyst. The 12.8% drop from the 30-day high appears sector-driven rather than idiosyncratic: Health Care (XLV) ranks 10th of 11 sectors by 30-day relative strength and is down ~12.5pts vs. SPY over 30 days, suggesting broad sector pressure accounts for much of the decline. The base rate for a fundamentally sound stock recovering a 10%+ dip within 90 days is ~55-60%, but meaningful headwinds temper conviction.
?May 22, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ZBH (Zimmer Biomet) is down 14.4% from its 30-day high with no visible fundamental catalyst in the evidence set — no earnings surprise, no SEC filings, no insider selling. However, the Health Care sector is deeply underperforming (rank 10/11, -13.87pts vs SPY over 30 days) with sharply negative sector flow (-$13.8M), suggesting this drop is largely sector-driven rather than idiosyncratic. The broad market is also under pressure today (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE 2.7, 2.5σ above trend) create a headwind for rate-sensitive healthcare names. With no confirmation signals — no insider buys, no unusual call flow, no analyst upgrades — the case for a rebound rests entirely on mean reversion in the sector, which is currently in a downtrend.
?May 21, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ZBH (Zimmer Biomet) is a large-cap medical devices company with no evidence of fundamental deterioration — no recent 10-Q/8-K filings flagging guidance cuts or going concerns, and no imminent earnings catalyst. The 12.8% drop from the 30-day high appears sector-driven rather than idiosyncratic: Health Care (XLV) ranks 10th of 11 sectors by 30-day relative strength and is down ~12.5pts vs. SPY over 30 days, suggesting broad sector pressure accounts for much of the decline. The base rate for a fundamentally sound stock recovering a 10%+ dip within 90 days is ~55-60%, but meaningful headwinds temper conviction.
?May 21, 6:00 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ZBH (Zimmer Biomet) is down 14.4% from its 30-day high with no visible fundamental catalyst in the evidence set — no earnings surprise, no SEC filings, no insider selling. However, the Health Care sector is deeply underperforming (rank 10/11, -13.87pts vs SPY over 30 days) with sharply negative sector flow (-$13.8M), suggesting this drop is largely sector-driven rather than idiosyncratic. The broad market is also under pressure today (SPY -1.20%, IWM -2.41%), and elevated inflation expectations (T5YIE 2.7, 2.5σ above trend) create a headwind for rate-sensitive healthcare names. With no confirmation signals — no insider buys, no unusual call flow, no analyst upgrades — the case for a rebound rests entirely on mean reversion in the sector, which is currently in a downtrend.
?May 21, 6:00 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
?May 21, 11:47 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ZBH (Zimmer Biomet) is a well-established large-cap medical device company with a diversified orthopedic portfolio, and the absence of any negative news headlines or SEC filings in the window suggests the ~12.8% drop is more likely attributable to macro or sector-rotation pressure rather than company-specific deterioration. However, the macro context flags elevated inflation expectations (T10YIE at 2.4σ above trend), which pressures healthcare/medical device multiples as discount rates rise and may weigh on longer-duration earnings streams. With no catalyst visible to drive a near-term rebound, and a meaningful headwind from the macro rate/inflation environment, confidence in a full recovery to the 30-day high within 90 days is modest.
▢May 18, 8:00 PMjournal
Agent 6 — Options Momentum opened long 100 @ $5.31

← Back to dashboard